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The Effect of Salsalate Therapy on Endothelial Function
in a Broad Range of Subjects
Anju Nohria, MD; Scott Kinlay, MBBS, PhD; J. Stewart Buck, BA; Whitney Redline, BA; Robert Copeland-Halperin, BA;
Sora Kim, BA; Joshua A. Beckman, MD
Background-—Inﬂammation is fundamental to the development of atherosclerosis. We examined the effect of anti-inﬂammatory
doses of salicylate on endothelium-dependent vasodilation, a biomarker of cardiovascular risk, in a broad range of subjects.
Methods and Results-—We performed a randomized, double-blind, placebo-controlled crossover trial evaluating the effects of
4 weeks of high-dose salsalate (disalicylate) therapy on endothelium-dependent ﬂow-mediated and endothelium-independent
vasodilation. Fifty-eight subjects, including 17 with metabolic syndrome, 13 with atherosclerosis, and 28 healthy controls, were
studied. Among all subjects, endothelium-dependent ﬂow-mediated vasodilation decreased after salsalate compared with placebo
therapy (P=0.01), whereas nitroglycerin-mediated, endothelium-independent vasodilation was unchanged (P=0.97). Endothelium-
dependent ﬂow-mediated vasodilation after salsalate therapy was impaired compared with placebo therapy in subjects with
therapeutic salicylate levels (n=31, P<0.02) but not in subjects with subtherapeutic levels (P>0.2).
Conclusions-—Salsalate therapy, particularly when therapeutic salicylate levels are achieved, impairs endothelium-dependent
vasodilation in a broad range of subjects. These data raise concern about the possible deleterious effects of anti-inﬂammatory
doses of salsalate on cardiovascular risk.
Clinical Trial Registration-—URL: www.clinicaltrials.gov. Unique Identiﬁers: NCT00760019 and NCT00762827. ( J Am Heart
Assoc. 2014;3:e000609 doi: 10.1161/JAHA.113.000609)
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A bundant evidence implicates inﬂammation in the path-ogenesis of atherosclerosis.1 The recent Justiﬁcation for
the Use of Statins in Prevention: an Intervention Trial
Evaluating Rosuvastatin (JUPITER) study, in which intensive
statin therapy reduced cardiovascular events compared with
placebo in patients with normal LDL cholesterol but high C-
reactive protein (CRP) levels, has intensiﬁed interest in the
therapeutic potential of anti-inﬂammatory therapy in cardio-
vascular disease.2 Clinical trials are currently under way
testing the efﬁcacy of proven anti-inﬂammatory drugs as
cardiovascular therapeutic agents.3,4
The proinﬂammatory transcription mediator nuclear factor
(NF)-jB has emerged as a potential therapeutic target in
cardiovascular disease.5 Both systemic pharmacological and
endothelium-speciﬁc targeting of NF-jB reduced plaque
burden in experimental atherosclerosis.6,7 Recently, endothe-
lium-speciﬁc transgenic blockade of the intracellular NF-jB
pathway reduced vascular inﬂammation and oxidative stress
and prevented vascular senescence in aged and obese mice.8
Low-dose salicylates (eg, aspirin 81 mg/day) are broadly
used in the prevention and treatment of atherosclerotic
vascular disease. At a low dose, suppression of platelet
thromboxane synthesis by aspirin dominates suppression of
endothelial prostacyclin synthesis, and a net antithrombotic
effect is achieved. A higher dose of salicylates (≥2 g/day) is
required to exert a systemic anti-inﬂammatory effect. The
underlying mechanism is not well understood but is proposed
to be in large part due to direct suppression of inhibitor of jB
kinase (IKK) activity, thereby limiting upregulation of NF-jB
activity.9
Salicylates may also improve insulin sensitivity by inhibit-
ing IKK-induced serine phosphorylation of insulin receptor
substrate-1.10 Indeed, high-dose salicylate therapy sup-
presses obesity- and diet-induced inﬂammation and insulin
resistance in experimental models.11,12 In clinical studies,
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high-dose salicylate therapy improves glycemia in diabetes
mellitus.13,14 The Targeting INﬂammation using SALsalate in
CardioVascular Disease (TINSAL-CVD) study (NCT00624923)
is currently testing the potential for high-dose salicylate
treatment to improve glycemia and reduce coronary artery
atherosclerotic plaque volume in diabetes.
Endothelial insulin signaling results in activation of endo-
thelial nitric oxide synthase (eNOS) and endothelium-depen-
dent, nitric oxide (NO)-mediated vasodilation. High-dose
salicylate therapy, by restoring endothelial insulin signaling,
may improve endothelial function in states of inﬂammation
and insulin resistance.15,16 We therefore hypothesized that
chronic high-dose salicylate therapy would improve endothe-
lial function in persons with insulin resistance, identiﬁed by
the presence of the metabolic syndrome, and in persons with
atherosclerosis. The results of our clinical translational study
suggest that high-dose salicylate therapy may not have the
intended effect on endothelial function.
Methods
Subject Selection
This report presents the combined results of 2methodologically
identical, simultaneously conducted studies (NCT00760019
and NCT00762827). One study involved subjects with the
metabolic syndrome and the other, those with atherosclerosis.
Each study also recruited a group of healthy controls that are
combined for the purpose of this analysis.
Subjects were recruited by advertisement and from the
clinical practices at Brigham and Women’s Hospital. The
presence of atherosclerosis was deﬁned as a prior myocardial
infarction, previous coronary lesion >70%, previous stroke or
transient ischemic attack, internal carotid artery stenosis
>70%, ankle-brachial index <0.90, or previous lower extremity
revascularization or amputation. The metabolic syndrome was
deﬁned as the presence of at least 3 of the following 5
symptoms as deﬁned by the National Cholesterol Education
Program (NCEP): abdominal obesity (waist circumference
≥88.9 cm for women, and ≥101.6 cm for men), impaired
fasting glucose (5.55 mmol/L [100 mg/dL] ≤ glucose<
6.99 mmol/L [126 mg/dL]), elevated fasting triglycerides
(≥1.69 mmol/L [150 mg/dL]), hypertension (blood pressure
≥135/85 mm Hg), and low HDL cholesterol (<1.30 mmol/L
[50 mg/dL] for women, or <1.04 mmol/L [40 mg/dL] for
men). For both groups, exclusion criteria included uncon-
trolled hypertension (≥160/100 mm Hg), untreated hyperlip-
idemia (LDL ≥4.14 mmol/L [160 mg/dL]), diabetes mellitus,
current tobacco use, hypersensitivity to salicylates, increased
bleeding risk (eg, thrombocytopenia, hemorrhagic stroke
within 1 year, or use of warfarin), ingestion of >5 alcoholic
beverages/week, elevation of liver enzymes (ALT ≥29 upper
limit of normal [ULN]), and serum creatinine ≥106.76 mmol/L
(1.4 mg/dL). Healthy subjects did not have a prior history of
cardiovascular disease or any symptoms, physical ﬁndings, or
electrocardiographic ﬁndings indicative of atherosclerosis.
Additional exclusion criteria included a chronic inﬂammatory
disorder (eg, rheumatoid arthritis), active malignancy, fasting
glucose ≥5.55 mmol/L (100 mg/dL), LDL ≥4.92 mmol/L
(190 mg/dL), blood pressure >140/90 mm Hg, smoking
within 1 year, serum creatinine ≥106.76 mmol/L (1.4 mg/dL),
and ALT ≥29 ULN.
Study Design
The study design was a randomized, placebo-controlled,
double-blind crossover trial. Treatment periods were 4 weeks
each, with a 4-week washout interval between treatments.
Four weeks was chosen based on a demonstrated effect of
salsalate in that time frame17 and to ensure repeat evaluation
at the same phase of the female reproductive cycle. The
Investigational Drug Service at Brigham and Women’s Hospital
performed randomization at the time of ﬁrst study drug
allocation. Study visits occurred at the end of each treatment
period. All tests were conducted in the morning after an
overnight fast.
Interventions
Treatment arms were salsalate 4.5 g/day or matching
placebo. Three 500-mg Disalcid tablets (Caraco Pharmaceu-
tical Laboratories) were taken 3 times daily. Subjects who
experienced a treatment-associated side effect were asked to
reduce the total dose to 4 and, if necessary, 3 g/day.
Treatment adherence was assessed by pill count. Ranitidine
150 mg twice daily (atherosclerosis study) (Apotex Corpora-
tion) or omeprazole 20 mg once daily (metabolic study)
(Sandoz, Inc) was administered during each treatment period
to minimize gastrointestinal intolerance.
A total of 126 subjects provided informed consent, and 56
completed the study. Fifty-seven subjects were excluded from
participation as a result of not meeting inclusion criteria. Of
the 69 subjects who met inclusion criteria and were offered
continued participation, 56 subjects completed the protocol
and 13 discontinued the study due to 1 or more adverse
events: tinnitus, 5; rash, 3; gastrointestinal distress, 3;
dizziness, 1; constipation, 2; and shortness of breath, 1.
These adverse events occurred at rates similar to those of
published clinical trials.13,18 Post hoc unblinding revealed that
1 constipation event and the shortness of breath event
occurred with placebo, while the other adverse events
occurred during salsalate treatment. Among those who
completed the study, 6 had study drug dose reduced to
3 g/day due to tinnitus, which resolved after dose reduction.
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Assessment of Vascular Function: Flow-Mediated
Vasodilation
Brachial artery ultrasonography was performed in a temper-
ature-controlled, quiet environment to evaluate vascular
function after each treatment period. An ultrasound scanner
(General Electric Vivid 7) equipped with a high-resolution
broadband linear array transducer (7.5 to 12.5 MHz) was
used to image the brachial artery. Endothelium-dependent
and -independent dilations of the brachial artery were
determined as we have done previously and according to
established guidelines.19,20
Two independent reviewers performed acquisition and
analysis of the digitized images in a blinded manner using
software from Medical Imaging Applications, LLC. The vessel
wall–lumen interface was determined using a derivative-based
edge detection algorithm after identiﬁcation of the region of
interest by the investigator. The maximum diameter of the
vessel was then determined. In our laboratory, this method is
associated with an interobserver variability of 0.050.16%
and intraobserver variability of 0.010.15%. The same arm
and site were used for all measurements.
Laboratory Measurements
Blood for laboratory assessment was collected after each
treatment period and was either processed immediately or
centrifuged and stored in aliquots in a 80°C freezer for
future analyses. The clinical laboratory personnel at Brigham
and Women’s Hospital performed routine laboratory tests.
Insulin levels were measured using the Beckman Access II
immunoassay platform (GMI, Inc). Salicylate levels were
measured using the Olympus AU640 analyzer (Beckman
Coulter Ltd). The concentration of nonesteriﬁed free fatty
acids (FFAs) was determined using an in vitro enzymatic
colorimetric assay on the Hitachi 917 analyzer (Roche
Diagnostics) with reagents from Wako Chemicals USA. High-
sensitivity CRP was measured using an immunoturbidimetric
assay on the Hitachi 917 analyzer (Roche Diagnostics) using
reagents and calibrators from DiaSorin. Tumor necrosis factor
(TNF)-a receptor 2 (TNF-aR2) was measured using an ELISA
from R&D systems. Myeloperoxidase concentrations were
determined using an ELISA from Alpco Diagnostics.
Statistical Analysis
Baseline characteristics are described as mean and SD or
median and interquartile range (IQR), as appropriate. Com-
parison of baseline characteristics between groups was
performed using ANOVA, Kruskal–Wallis equality-of-popula-
tions test, or v2 test, as appropriate. The primary outcome
assessment was to compare brachial artery FMD response
after placebo with that after salsalate therapy. The distribution
of FMD at both time points was not normally distributed
(P=0.036 by Shapiro–Wilk test). Consequently, a Wilcoxon
signed-rank analysis was performed to assess the difference
in median FMD between salsalate and placebo (the primary
endpoint). We then used repeated-measures ANOVA to
assess carryover effect with terms for treatment (salsalate
versus placebo), period (salsalate given ﬁrst or second), and
their interaction. Separate models assessed treatment effects
on FMD and interactions between treatment and disease
(atherosclerosis, metabolic syndrome, or controls) and the
effect of salsalate on endothelium-independent vasodilation,
glucose homeostasis, fatty acids and lipids, and biomarkers of
inﬂammation. Other subgroup descriptive analyses were by
the paired Student t test or the Wilcoxon signed-rank test, as
appropriate. STATA/IC version 11.2 for MAC (StataCorp) was
used for all analyses.
Results
Subject Characteristics
The subjects had a mean age of 56 years (Table 1). The mean
age varied between subject groups, with the oldest being
those with atherosclerosis. The mean body mass index was
30 kg/m2, with the highest body mass index among those
with the metabolic syndrome. The distribution of sex and race
did not vary signiﬁcantly between groups.
The mean plasma salicylate concentration during salsalate
treatment among all subjects (0.900.69 mmol/L [12.49.5
Table 1. Baseline Characteristics of the Study Subjects
All Healthy Controls Patients With Metabolic Syndrome Patients With Atherosclerosis P Value
N 58 28 17 13 n/a
Age, y 56 (11) 52 (13) 57 (9) 65 (8) 0.005
Men, N (%) 38 (65) 16 (57) 10 (59) 12 (92) 0.07
White, N (%) 44 (76) 21 (75) 11 (65) 12 (92) 0.21
BMI, kg/m2 30 (7) 26 (4) 35 (6) 28 (4) <0.001
Data are presented as mean (SD) or number (%). BMI indicates body mass index.
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mg/dL]) was within the therapeutic range (0.72 to
2.17 mmol/L [10 to 30 mg/dL]). Mean salicylate levels
during salsalate treatment varied by subject group (P=0.01).
The mean level in those with atherosclerosis (1.36
0.74 mmol/L [18.810.2 mg/dL]) was higher than healthy
subjects (0.730.69 mmol/L [10.19.5 mg/dL]) and those
with the metabolic syndrome (0.800.49 mmol/L [11.0
6.7 mg/dL]). Overall, 54% (n=30) of subjects’ had salicylate
levels within the therapeutic range. The proportion of subjects
with salicylate levels below the therapeutic range did not vary
between groups (P=0.19).
Flow-Mediated Vasodilation
Among all subjects, baseline brachial artery diameter and the
postocclusion reactive hyperemia stimulus were not different
after placebo compared with after salsalate therapy (Table 2).
Median FMD was signiﬁcantly less after salsalate treatment
(6.8% [IQR=5.2, 12.0]) compared with placebo treatment
(8.7% [IQR=5.4, 13.5]) (P=0.01) (Figure 1). Nitroglycerin-
mediated, endothelium-independent vasodilation was not
different after placebo (12.6% [IQR=8.6, 19.7]) and salsalate
(13.0% [IQR=8.5, 17.0]) treatments (P=0.97) (Figure 2).
In separate models, repeated-measures ANOVA showed no
signiﬁcant carryover effect (treatment9period interaction
P=0.57) and no signiﬁcant difference in treatment effect
between the subject groups with atherosclerosis or metabolic
syndrome or healthy subjects (treatment9group interaction
P=0.26). In post-hoc analyses, within individual subject
groups, FMD was lower in each group after salsalate compared
with after placebo but reached statistical signiﬁcance only in
the subjects with atherosclerosis (P=0.009). Nitroglycerin-
mediated vasodilation did not change after salsalate treatment
compared with placebo in any subject group.
Insulin Resistance and Inﬂammation
Fasting insulin levels trended higher after salsalate compared
with after placebo (Table 3). Fasting glucose levels decreased
signiﬁcantly with salsalate treatment compared with placebo
treatment, P=0.001). The rise in insulin and fall in glucose
levels offset such that homeostatic model assessment insulin
resistance (HOMAIR) did not differ after salsalate compared
with placebo treatment.
We measured plasma CRP, TNF-aR2, and myeloperoxidase
as markers of systemic inﬂammation. Levels of these markers
were not signiﬁcantly different after salsalate compared with
placebo among all studied subjects or within any subject
group (Table 3).
Table 2. Vascular Function Parameters
Treatment
Baseline
Diameter,
mm
RH
Stimulus FMD, % NMD, %
Placebo 3.8 (3.3
to 4.3)
5.8 (3.9
to 8.1)
8.7 (5.4
to 13.5)
12.6 (8.6
to 19.7)
Salsalate 3.9 (3.3
to 4.3)
6.3 (4.8
to 9.5)
6.8* (5.2
to 12.0)
13.0 (8.5
to 17)
Data are presented as median (IQR). FMD indicates ﬂow-mediated dilation; NMD,
nitroglycerin-mediated dilation; RH, reactive hyperemia.
*P=0.027.
Figure 1. Flow-mediated, endothelium-dependent vasodilation of the brachial artery after placebo (P) and salsalate (S) therapy. Data shown are
median (IQR). ATHERO indicates atherosclerosis; MET, metabolic syndrome.
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Other Parameters
Salsalate therapy did not change total or LDL cholesterol
levels (Table 4). Triglycerides and FFAs were lower after
salsalate therapy compared with placebo in all subjects
combined, with a consistent trend in each individual subject
group. HDL cholesterol was signiﬁcantly higher in control
subjects after salsalate treatment compared with placebo,
with a numerically higher but not signiﬁcantly different HDL
level in the other subject groups. Of all the parameters
measured, only the change in triglycerides associated with the
change in FMD. Salsalate-mediated reductions in triglyceride
level correlated inversely with changes in FMD (Spearman’s q
0.32, P=0.014). The inclusion of triglycerides as a covariate
in a repeated-measures ANOVA model with treatment
indicated a signiﬁcant positive effect of a fall in triglycerides
and improved FMD (P=0.002) and strengthened the signiﬁ-
cance of the adverse treatment effect of salsalate on FMD
(treatment P=0.004).
Salsalate therapy did not inﬂuence systolic or diastolic
blood pressure. Serum creatinine was signiﬁcantly higher
after salsalate treatment compared with placebo, consistent
with the previously described observation that salicylate
decreases creatinine clearance independent of a change in
the glomerular ﬁltration rate.21
Results Stratiﬁed by Therapeutic Versus
Nontherapeutic Salicylate Level
A salicylate level of ≥0.72 mmol/L (10 mg/dL) is considered
necessary to achieve a systemic anti-inﬂammatory effect.22
We therefore repeated our analysis of the effects of salsalate
on FMD with subjects stratiﬁed by subtherapeutic
(<0.72 mmol/L, n=27) or therapeutic (≥0.72 mmol/L,
n=30) salicylate levels (Figure 3). We observed a signiﬁcant
decrement in FMD after salsalate compared with placebo
therapy when therapeutic salicylate levels were achieved. In
contrast, salsalate therapy did not alter endothelial function
when salicylate levels were subtherapeutic (P=0.95). The
brachial artery response to nitroglycerin was not inﬂuenced by
salicylate level, nor was the brachial artery baseline diameter
or the reactive hyperemia stimulus.
Analyses of CRP, TNF-aR2, and myeloperoxidase stratiﬁed
by therapeutic versus subtherapeutic salicylate level revealed
lower myeloperoxidase levels (P=0.009) and a trend toward
lowers TNF-aR2 levels (P=0.07) when therapeutic salicylate
levels were achieved. Despite a signiﬁcant reduction in
oxidant markers and a favorable trend in inﬂammatory
markers, there was no association between the change in
either oxidant or inﬂammatory markers and FMD. In contrast,
there was no treatment effect on these inﬂammatory markers
in subjects with subtherapeutic salicylate levels.
Discussion
The anti-inﬂammatory effects of salicylates prompted us to
examine the effect of salsalate on endothelial function.
Contrary to our expectations, salsalate therapy was associ-
ated with impaired endothelium-dependent vasodilation. This
was particularly true when therapeutic salicylate levels were
achieved at the time of vascular function testing. Salsalate did
not alter endothelium-independent vasodilation, indicating
Figure 2. Nitroglycerin-mediated, endothelium-independent vasodilation of the brachial artery after placebo (P) and salsalate (S) therapy. Data
shown are median (IQR). ATHERO indicates atherosclerosis; MET, metabolic syndrome.
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that the observed attenuation in vascular function was
speciﬁc to the endothelium. This occurred in a broad range
of subjects including healthy individuals, subjects with the
metabolic syndrome, and those with atherosclerosis, sug-
gesting that salsalate-induced impairment in endothelial
function is largely independent of the underlying health of
the endothelium. Given that endothelium-dependent vasodi-
lation is a biomarker for cardiovascular risk, these results
suggest caution against pursuing anti-inﬂammatory high-dose
salicylate therapy as a strategy to prevent or treat cardiovas-
cular disease.
The Effect of Salicylate on Endothelium-
Dependent Vasodilation
Contrary to our hypothesis, salsalate therapy attenuated
endothelium-dependent vasodilation. While our study cannot
determine the mechanism by which salicylate impaired
endothelium-dependent vasodilation, we speculate that salic-
ylate reduced the bioavailability of 1 or more of the endothe-
lium-derived vasodilators: NO, prostacyclin, and the
endothelium-derived hyperpolarizing factors. The mean reduc-
tion in FMD after salsalate therapy in healthy controls and in
subjects with atherosclerosis was 16% and 44%, respectively.
In our laboratory, complete inhibition of NO by NG-monom-
ethyl-L-arginine reduced FMD by 75% in healthy subjects and
by 25% in subjects with atherosclerosis.23 This would suggest
that salsalate impairs a vasodilator other than NO or a
combination of NO and another endothelium-derived vasodi-
lator. Salsalate does not directly inhibit cyclooxygenase but
can limit the up-regulation of cyclooxygenase-2 in the setting
of inﬂammation.24 Clinical studies have shown that selective
cyclooxygenase-2 inhibition does not alter endothelium-
dependent vasodilation in healthy vessels,25 and either no
change or an improvement in endothelium-dependent vasodi-
lation with cyclooxygenase-2 inhibition has been reported in
atherosclerosis.26,27 We therefore suspect that impairment in
1 or more of the endothelium-derived hyperpolarizing factors
may in part account for our ﬁndings. In addition to arachidonic
acid metabolites derived from the cyclooxygenases, endothe-
lium-derived hyperpolarizing factors include arachidonic acid
metabolites derived from lipoxygenases and cytochrome P450
pathways, hydrogen peroxide, carbon monoxide, and hydrogen
sulﬁde. Additional experiments using inhibitors of each of
these vasodilators are necessary to discern which, if any, of
the endothelium-derived vasodilators play a role in salsalate-
mediated reduction in endothelium-dependent vasodilation.
We are not aware of a study examining the effect of high-
dose salicylate therapy on endothelial function in a preclinical
model. Pierce et al found that 13 of 14 overweight/obese
middle-aged and older adults demonstrated improvement in
brachial artery FMD after 4 days of high-dose salicylate
compared with placebo therapy.28 In addition, they found that
subjects with the most impaired FMD at baseline experienced
the greatest improvement after salsalate therapy. These
results are the opposite of those observed in our study.
Figure 3. Flow-mediated, endothelium-dependent vasodilation of the brachial artery after placebo (P) and salsalate (S) therapy in subjects with
a therapeutic salicylate level and those with a subtherapeutic level. Data shown are median (IQR).
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Shorter duration of therapy and occlusive cuff location are the
major differences between these studies’ design, though it is
unclear how either of these would account for the discordant
results. Mean salicylate levels were lower overall in our study;
however, higher therapeutic salicylate levels correlated with
the most severe impairment of FMD (r=0.36, P=0.05 in
patients with therapeutic salsalate levels).
Few other clinical studies examining the effect of high-dose
salicylate therapy on endothelial function are available.
Salsalate therapy has had conﬂicting results on endothelial
function in patients with HIV.29,30 Tabit and colleagues found
no effect of sulfasalazine therapy on endothelial function in
patients with coronary artery disease.31 Similarly, Goldﬁne
et al found no difference in FMD in diabetic subjects treated
with high-dose salsalate therapy.32 Thus, it appears that a
deﬁnitive conclusion about the effect of salicylate therapy on
endothelial function cannot be drawn from the available data.
Our results raise the possibility of an adverse cardiovas-
cular effect of salsalate when present in therapeutic concen-
trations. Medications beneﬁcial for cardiovascular disease
have been shown to increase ﬂow-mediated vasodilation,
such as statins19 or angiotensin-converting enzyme inhibi-
tors.33 However, there is no stimulus that impairs endothelial
function that is associated with improved cardiovascular
outcomes. Even medications that improve outcomes in cancer
but worsen endothelial function increase adverse cardiovas-
cular events.34,35 These ﬁndings suggest that salsalate may
require a clinical trial to ensure its safety in patients with
cardiovascular disease.
Salicylate and Insulin Resistance
Salicylate improves insulin sensitivity in experimental models,
in part due to inhibition of IKK and prevention of serine
phosphorylation of insulin receptor substrate-1.16 Clinical
studies, however, have had mixed results. Two groups of
investigators found that acetylated salicylate decreased insu-
lin-stimulated glucose disposal in healthy subjects.36,37 In
contrast, high-dose aspirin increased insulin-stimulated
glucose disposal by 25% in subjects with type 2 diabetes.38
Goldﬁne and colleagues reported that high-dose salsalate
improved insulin-stimulated glucose disposal by 43% in diabe-
tes, and they subsequently showed that long-term salsalate
therapy achieved a 0.5% improvement in HbA1c.13,14 More
recently, Goldﬁne and colleagues have published a large
randomized trial of salsalate showing reductions in fasting
glucose and an increase in fasting insulin.32 HOMAIR, however,
remained similar at baseline and after salsalate therapy. Other
groups, as well, did not ﬁnd that salsalate improved insulin
resistance.39,40–42 In total, the available data do not provide a
clear view of the effect of high-dose salsalate therapy on insulin
resistance.
Effect of Salicylate on Lipid Metabolism
Salsalate therapy signiﬁcantly reduced FFA levels, as ﬁrst
reported by Carlson and Osiman.43 This is likely in part due to
salicylate directly inhibiting release of FFAs from adipocytes,
improving insulin signaling, and preventing TNF-a–induced
lipolysis.44,45 Reduction of FFA levels might be expected to
improve endothelial function and/or insulin sensitivity in
states of insulin resistance,16,46 but despite FFA levels falling
30% after salsalate therapy, no such improvements were
noted in our study.16,46 We also observed a fall in triglyce-
rides, possibly because of a direct relation between IKK-b
activation and triglyceride production within the hepatocyte.47
The decrease in triglyceride production provided a modest
compensatory support for ﬂow-mediated vasodilation, but its
effect was inadequate to offset the deleterious effect of
therapeutic salicylate levels.
The Anti-inﬂammatory Effect of Salicylate
The potential beneﬁt of salicylate therapy on endothelial
function is rooted in the anti-inﬂammatory effects of salicylate
and the adverse effects of inﬂammation on NO bioavailability.48
However, the mechanisms underlying the anti-inﬂammatory
effect of salicylates are not well understood. Several potential
mechanisms by which salicylates are anti-inﬂammatory have
been proposed, and much of the focus has been on the ability
of salicylate to inhibit the proinﬂammatory kinase IKK.49 IKK
activates the proinﬂammatory and proatherosclerotic tran-
scription mediator NF-jB. Pharmacological or genetic inhibi-
tion of NF-jB reduces aortic atherosclerotic plaque burden in
atherosclerotic mice.6,7 Thus, NF-jB suppression is a
potential way in which salicylates are both anti-inﬂammatory
and antiatherosclerotic. However, it has also been proposed
that salicylate exerts its anti-inﬂammatory effects indepen-
dent of NF-jB.24,50–52 Goldﬁne and colleagues have reported
that adipose tissue NF-jB activity declines with salsalate
treatment, but it did not correlate with metabolic improve-
ments.32 Similarly, Tabit and colleagues have shown sulfasal-
azine-mediated reductions in NF-jB–regulated gene
expression in peripheral blood mononuclear cells, but this
treatment did not restore endothelial function in patients with
coronary artery disease.53 Despite multiple postulated mech-
anisms, we found only minor changes in circulating markers
of inﬂammation after salsalate therapy and cannot establish a
role for anti-inﬂammatory effects of this medication.
Conclusion
In this randomized, placebo-controlled crossover trial of
4 weeks of high-dose salsalate therapy in healthy control
DOI: 10.1161/JAHA.113.000609 Journal of the American Heart Association 8
Salsalate and Endothelial Function Nohria et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
subjects, subjects with the metabolic syndrome, and subjects
with atherosclerosis, we observed that high-dose salsalate
therapy worsened endothelial function and did not improve
insulin sensitivity. Though favorable effects on FFA and
triglyceride levels were observed, in total these data raise
concern about the potential effects of long-term high-dose
salicylate therapy on cardiovascular risk.
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